Answers are grounded in this paper and cite their sources.
Cancers with an unidentified primary site at the start of treatment are classified as cancers with an unknown original primary site. Their prevalence among cancer patients is around 5%. One of challenges in medicine is an approach to those patients. The requirement for the early detection of malignancies or palliative care are still problem in medicine. A strategy for their treatment should be created to avoid prolong hospital stays and testing that won't improve therapy or the prognosis for those sufferers. It's crucial to identify individuals whose diseases have good prognoses since they may benefit greatly from targeted therapy, including longer survival. A targeted search for the main tumor in those patients is advised. However, for those patients who will effectively employ targeted therapies, the combination of a robust immunohistochemistry panel with novel molecular knowledge may enable the development of a specific management strategy.
No takes yet. Share an insight, caveat, or question.
A.AL-Ali et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: